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How Can Software SMEs become Medical Device 
Software SMEs 
Fergal Mc Caffery, Valentine Casey, and Martin Mc Hugh 
Regulated Software Research Group,  
Dundalk Institute of Technology & Lero, Dundalk, Co. Louth, Ireland  
{fergal.mccaffery,val.casey,Martin.McHugh}@dkit.ie 
Abstract. The amount of software content within medical devices has grown 
considerably over recent years and will continue to do so as the level of com-
plexity of medical devices increase.  This is driven by the fact that software is 
introduced to produce sophisticated medical devices that would not be possible 
using only hardware. This therefore presents opportunities for software devel-
opment SMEs to become medical device software development organisations. 
However, some obstacles need to be addressed and overcome in order to make 
the transition from being a generic software development organisation to  
becoming a medical device software development organisation. This paper  
describes these obstacles and how research that is currently being performed 
within the Regulated Software Research Group in Dundalk Institute of  
Technology may be used to assist with this transition. 
Keywords: Medical device software, Software development, Software process 
improvement and assessment, Medi SPICE, Medical device standards, SME’s. 
1   Introduction - Background to Medical Device Software 
Development  
Today software is an increasingly important component of medical devices, as it  
enables often complex functional changes to be implemented without necessitating   
changes to the hardware [1]. As a consequence of the increasing demands for greater 
functionally within medical devices, the complexity of medical device software  
development also continues to  increase [2]. This has resulted in increased demand for 
appropriate traceability and risk management processes and tools.  
It is very important that highly effective software development practices are in 
place within medical device companies due to the safety-critical nature of medical 
device software. In order to sell their products medical device companies must com-
ply with the regulatory requirements of the countries in which they wish to market 
their devices [3]. Governments have put in place regulatory bodies to tackle these 
issues whose role is to define regulatory systems for medical devices and to ensure 
that only safe medical devices are placed on the market [4].  
While regulatory bodies offer some guidance on what software activities must be 
performed, no specific method for performing these activities is provided or enforced 
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[5]. In this context in the United States (US), the Food and Drug Administration 
(FDA) Center for Devices and Radiological Health (CDRH) has published guidance 
papers which include risk-based activities to be performed during software validation 
[6], pre-market submission [7] and when using off-the-shelf software in a medical 
device [8].  Although the CDRH guidance documents provide information on which 
software activities should be performed, they do not enforce any specific method for 
performing these activities. This can result in medical device software companies 
failing to comply with the expected requirements. 
To help address this situation a decision was taken by the medical device industry 
to recognize ISO/IEC 12207:1995 [9] (a general software engineering lifecycle proc-
ess standard) as suitable for general medical device software development.  Subse-
quently the Association for the Advancement of Medical Instrumentation (AAMI) 
software committee carefully reviewed ISO/IEC 12207:1995 and identified a number 
of shortcomings due to the fact that it was a generic standard. This resulted in the 
decision to create a new standard which was domain specific to medical device soft-
ware development. The AAMI did not discard the work done with the ISO/IEC 
12207:1995 and used it as the foundation for their new standard “AAMI SW68, 
Medical device software – Software lifecycle processes” [10]. In 2006, a new stan-
dard IEC 62304 [11] was released that was based on the AAMI SW68 standard. 
The Council of the European Communities published in 1993  the  Directive 
93/42/EEC (1993) [12], the “Medical Device Directive” (MDD), on medical devices. 
The MDD is intended to ensure the safety of medical devices placed on the market in 
the European Union (EU), and has the backing of national legislation in member 
states.  Amendments to this directive occurred via Directives 2000/70/EC (2000) [13], 
2001/104/EC (2001) [14], 2003/32/EC (2003) [15], and 2007/47/EC (2007) [16].   
Whenever we mention medical device guidelines within this paper we refer to the 
following medical device standards and guidelines: IEC 62304, FDA, the MDD, ISO 
14971 [17], EN 60601-4 [18], TIR 32 [19], IEC TR 80002-1[20], IEC 62366 
[21],GAMP 5 [22], IEC/TR 61508 [23], ISO 13485[24] and IEC 60812 [25].  
The remainder of this paper is structured in the following way.  Section 2 considers 
the reasons why software Small and Medium sized Enterprises (SMEs) are interested 
in becoming medical device SMEs and the challenges they face.  In section 3 recent 
changes made by the EU and FDA regarding medical device software are discussed. 
Section 4 outlines the research currently being undertaken by the Regulated Software 
Research Group (RSRG) in Dundalk Institute of Technology which is of particular 
value to assist SMEs to develop medical device software.  Section 5 discusses what 
initial steps can be taken by SMEs when embarking on medical device software de-
velopment. A conclusion is provided in section 6 and future work is outlined. 
2   Why Software SMEs Are Interested in Becoming Medical 
Device SMEs 
Software development SMEs are currently becoming medical device software  
development SMEs for two main reasons. The first of these is medical devices are 
becoming increasingly more complex and software facilitates increased functionality 
without the necessity to replace hardware. Therefore, due to growth in this area for 
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this type of software there is an opportunity for software development SMEs to   
become medical device software development SMEs. The second reason is that soft-
ware development SMEs currently developing health related software applications 
may now be actually developing medical device software.  This is due to the most 
recent  revision of the of Medical Device Directive [16], which states that standalone 
software may now be defined as a medical device. 
The challenge both types of organizations face is that to become a medical device 
software SME requires that software be developed in a regulatory compliant manner. 
This is essential as in order for a medical device to be marketed it is first necessary to 
achieve regulatory approval for the device in the region where it will be sold. This 
therefore means that such organizations need to become aware of what developing 
regulatory compliant software means and how they will have to change their current 
software development processes in order to fulfill this requirement. The starting point 
for such organizations is to become aware of the relevant regulations.  
3   Changes Impacting Medical Device Software  Development 
As medical devices are safety critical, they are subject to stringent regulations before 
they can be approved for use. Within the US medical devices must be approved by the 
FDA and likewise, medical devices for use within the EU must carry a CE confor-
mance mark. This is awarded by notified bodies in each country. The most recent 
changes in the regulations, with regard to medical device software development, is the 
European MDD (2007/47/EC) [16] and the FDA Final Rule on Medical Device Data 
Systems [26] 
On March 21st 2010, the MDD (2007/47/EC) came into force in the EU. This di-
rective amends the MDD (93/42/EEC) [12], the Active Implantable Medical Device 
directive (90/385/EEC) [27] and the Biocides directive (98/8/EC) [28]. The most 
significant amendment within the MDD (2007/47/EC) is the provision for standalone 
software to be used as an active medical device.  The MDD (2007/47/EC) Annex IX 
Section 1.4 states: “stand-alone software is considered to be an active medical de-
vice”. It defines an active medical device as “any medical device operation which 
depends on a source of electrical energy or any source of power other than that gen-
erated by the human body or gravity”[16]. 
Consequently, standalone medical device software is now subject to regulation, in-
dependent of the hardware on which it resides. As software can now be seen as the 
only component of a medical device, improved guidance is needed in the develop-
ment of this type of software to achieve regulatory compliance. While the MDD pro-
vides medical device manufacturers with a list of harmonized standards which can be 
used during development to aid in achieving regulatory compliance. However, no 
harmonized standards exist that can provide full guidance in the development of 
standalone software as an active medical device.  The FDA does not provide software 
or standalone software specific regulations. They regulate medical devices and the 
elements that are included as part of that device, with software being regulated in this 
context. To help address this the FDA provide relevant guidance documents to assist 
with medical device software development [7], [6], [8]. 
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On April 18th 2011, the FDA Final Rule reclassifying Medical Device Data sys-
tems (MDDS) as Class I medical devices became effective [26]. MDDS’s are off-the-
shelf or custom software or hardware products used alone, or in combination, that 
display unaltered medical device data or transfer, store or convert medical device data 
for future use, in accordance with a pre-set specification. Prior to the release of this 
final rule, MDDS were classified as Class III devices or as an accessory to the parent 
device, requiring the greatest amount of scrutiny before approval could be awarded. 
Whilst this ruling will make it simpler for companies developing MDDS software, 
it will also ring fence those which were previously beyond the net of regulatory re-
quirements and make them subject to regulation.  In addition, as part of this final rule 
a caveat was added to exclude devices that are used to actively monitor patients from 
being included as a MDDS. These devices remain classified as accessories and must 
undergo the same amount of regulatory conformance as the parent device to which 
they are connected [29]. Also standalone software such as Electronic Health Records 
(EHR) and Computerized Physician Order Entry (CPOE) fall outside of the scope of 
being defined as MDDS. 
4   Research to Help SMEs Develop Medical Device Software  
The RSRG was established in Dundalk Institute of Technology  in February 2008.   
The research undertaken by the RSRG is focused on the development of an interna-
tional Software Process Improvement (SPI) framework for the medical device indus-
try. The objective of this framework is to provide a key enabler of best practice for the 
sector. 
The RSRG have undertaken a multi-faceted approach to establishing this frame-
work including the examination of best practice from other safety-critical domains 
and determining how best practice SPI models can be successfully mapped onto regu-
latory frameworks.  This has taken place through close cooperation with the medical 
device industry, relevant international standards bodies and the software process im-
provement community.  A key element of this research is the use of empirical studies 
of industrial practice which has been utilized to inform theory.  To undertake this 
work the RSRG have adopted a range of quantitative and qualitative research meth-
odologies including experiments, quantitative analysis of data sets, case studies, ac-
tion research and grounded theory to provide a rich analysis of the domain. 
The main focus of the RSRG is to support the growth of the medical device soft-
ware industry within Ireland. However, this does not mean that their research has 
been restricted to Ireland, in fact the RSRG collaborates closely with international 
medical device organizations and SPI researchers. In particular, the RSRG is working 
as part of an international working group to revise the International Standard for 
Software Medical Device Software Lifecycle Processes (IEC 62304) and also closely 
with the Spice User Group to develop Medi SPICE [30]. Whilst the main deliverable 
for the RSRG is Medi SPICE they have also developed a number of lightweight as-
sessment methods to assist software SMEs to become medical device software SMEs. 
The following subsections describe Medi SPICE and the lightweight assessment 
methods Med-Trace, Med-Adept and Medi SPICE-Adept. 
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4.1   Medi SPICE 
Medi SPICE [30], [5] is a process assessment and improvement model which is do-
main specific to medical device software development and incorporates regulatory 
compliance.  The results of a Medi SPICE assessment may be used to indicate the 
state of a medical device suppliers software practices in relation to the regulatory 
requirements of the industry, and identify areas for process improvement. The results 
of an assessment may also be used as a criterion for supplier selection.  
Medi SPICE is based upon ISO/IEC 15504-5 [31] and provides coverage of the 
medical device software regulations. Like ISO/IEC 15504-5 and Automotive SPICE 
[32] it contains both a Process Reference Model (PRM) and Process Assessment Model 
(PAM) containing processes that provide comprehensive coverage of the FDA and 
European Council directives, and associated standards (e.g. ISO 14971, ISO 13485, IEC 
TR 80002-1,  IEC 62304) for the complete software development lifecycle. 
The overall objective of Medi SPICE is to provide a conformity assessment 
scheme to support first, second or third party assessment results that may be recog-
nized by the regulatory bodies. The PRM and PAM of the Medi SPICE assessment 
model is derived from relevant ISO/IEC 15504-5 processes as they are all applicable 
to the development of safety-critical medical device software. As the IEC 62304 stan-
dard contains the medical device software lifecycle processes that have to be adhered 
to in order to achieve medical device regulatory compliance, a key objective is to 
provide coverage of all processes that are either included in or referenced from IEC 
62304 and its associated standards. 
The Medi SPICE PRM and PAM is being released in phases and consists of a de-
fined set of software processes that contain a comprehensive set of specific practices 
which when utilized assist medical device software development organizations to 
fulfill the regulatory guidelines and standards of the medical device industry.  It also 
addresses the requirements for process assessment and can be utilized to facilitate 
process improvement.  
4.2   Med-Trace 
As traceability is central to the development of regulatory compliant software the 
RSRG decided to develop an assessment method specifically to assist companies to 
adhere to the traceability aspects of the medical device software standards. Emanating 
from the Adept method [33], previously developed by the authors, and based upon 
CMMI® [34] and ISO/IEC 15504-5 software process reference models, Med-Trace is 
a lightweight assessment method that provides a means of assessing the capability of 
an organization in relation to medical device software traceability.  Med-Trace en-
ables software development organizations to gain an appreciation of the fundamental 
traceability best practices based on the software engineering traceability literature, 
software engineering process models (CMMI®, ISO/IEC 15504-5), and the medical 
device software guidelines and standards. Med-Trace may be used to diagnose an 
organization’s weaknesses and strengths with relation to their medical device soft-
ware development traceability practices.  
Med-Trace is composed of 8 stages. The assessment team typically consists of two 
assessors who conduct the assessment between them.  Stage 1, involves a preliminary 
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meeting between the assessment team and the company wishing to undertake a Med-
Trace assessment. At stage 2, the lead assessor presents an overview of the Med-
Trace assessment to members of the organization who will be involved in subsequent 
stages. Stage 3, provides a brief insight into project documentation.  The first 3 stages 
are normally performed on the company’s premises, but the sample documentation 
collected in stage 3 is sometimes taken off-site as it can then be used to assist with the 
generation of additional questions for stage 4.  
During stage 4, the assessment team return onsite and key staff members from the 
organization are interviewed.  A set of scripted questions are utilized as a basis for 
these interviews. These questions are based upon the software traceability literature, 
traceability practices within the CMMI® and ISO/IEC 15504-5 models, and traceabil-
ity practices that are required by the medical device industry. Additional questions 
may be asked based on the review of the documentation outlined in stage 3. 
 Stage 5, is a collaborative exercise between the assessors to develop the findings 
report using interview notes.  Stage 6, involves presenting the findings report to par-
ticipating staff in the organization. Stage 7, entails collaborating with staff to develop 
a pathway towards achieving highly effective and regulatory compliant traceability 
practices. The findings report provides guidance to the assessed company and focuses 
on practices that provide the greatest benefit in terms of the company’s business 
goals, in addition to their quality and compliance needs.  
At Stage 8, the assessed company is revisited approximately 3 months after the 
completion of stage 7 and their progress is reviewed against the recommended im-
provement path. The outcome of this stage is an updated improvement path and a 
final report detailing the progress that has been accomplished along with additional 
recommendations. 
4.3   Med-Adept 
The Adept method [33] was previously developed to provide a lightweight assessment 
of software processes from CMMI® and ISO/IEC 15504-5 and was not domain spe-
cific. The Adept method was then integrated with practices specified in medical de-
vice regulatory guidelines and standards to produce Med-Adept. Med-Adept [35] is 
an assessment method that provides a means of assessing the software engineering 
capability for processes in relation to medical device software (both application and 
embedded software). 
Med-Adept enables software development organisations to gain an appreciation of 
the fundamental processes from CMMI®, ISO/IEC 15504-5 and IEC 62304 (including 
additional practices required by other medical device guidelines and standards) 
through diagnosing strengths and weaknesses in their software development practices. 
Med-Adept was designed to adhere to 8 of the 10 criteria outlined by Anacleto et al. 
[36], for the development of lightweight assessment methods: low cost, detailed de-
scription of the assessment process, guidance for process selection, detailed definition 
of the assessment model, support for identification of risks and improvement sugges-
tions, conformity with ISO/IEC 15504-5, no specific software engineering knowledge 
required from companies’ representatives, and tool support is provided. The two ex-
ceptions to the criteria outlined  by Anacleto et al. [36] are that no support is provided 
for high-level process modeling and only the authors currently have access to the 
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method. Med-Adept also inherits the following requirements from Adept: improve-
ment is more important than certification, a rating is not required, preparation time 
required by the company is minimised; assessment time is minimized, and companies 
should be enabled to select assessment in  the process areas that are most relevant to 
their business goals. 
The main aims of Med-Adept are to either encourage non-medical device software 
development organisations to develop software for the medical device industry or to 
improve the software development processes within existing medical device software 
development organizations. However, the Med-Adept method also provides an ideal 
opportunity to educate software development organisations in terms of generic SPI.  
Therefore, the assessment would still have value even if the assessed software devel-
opment company did not intend becoming a medical device software development 
company in the future. Consequently, Med-Adept provides medical device specific 
and non-medical device specific recommendations.  Assessed companies are also 
supplied with feedback in relation to both CMMI® and ISO/IEC 15504-5 which en-
ables such companies to decide whether they wish to follow a CMMI® or an ISO/IEC 
15504-5 improvement path. Med-Adept provides the assessed company with a find-
ings document presented in terms of processes from CMMI®, ISO/IEC 15504-5 and 
practices required by medical device software standards and regulations (with a par-
ticular focus on IEC 62304).   
Med-Adept is composed of 8 stages which are similar to those in Adept and Med-
Trace. The assessment team consists of two assessors who conduct the assessment 
between them. Stage 1 involves a preliminary meeting between the assessment team 
and the software company wishing to undergo a software process assessment.  The 
assessment team discuss the main drivers for the company embarking upon a Med-
Adept assessment and establish whether the company is interested in developing 
software for the medical device industry. During stage 2 the lead assessor provides an 
overview of Med-Adept for members of the assessed organisation who will be in-
volved in subsequent stages. This session is used to remove any concerns that indi-
viduals may have. 
Stage 3 provides a brief review of project documentation. However, the primary 
source of data for Med-Adept is through a series of process interviews conducted 
during stage 4. In this stage key staff members from the assessed organisation are 
interviewed. There is an interview for each process. Each interview is scheduled to 
last approximately 1.5 hours. To enable stage 4 to be completed within 1 day the 
scope of a single Med-Adept assessment is restricted to 4 processes. Each interview 
involves two assessors and at least one representative from the company. Stage 5 is a 
collaborative exercise between the assessors to develop the findings report using in-
terview notes for each of the assessed processes. The resultant findings report consists 
of a list of strengths, issues and suggested actions for each of the assessed processes.   
Stage 6, involves presenting the findings report to participating staff in the organi-
sation. Stage 7, involves collaborating with staff to develop a roadmap.  This provides 
guidance to the assessed company presenting practices that can provide the greatest 
benefit in terms of the company’s business goals. Companies wishing to develop 
software for the medical device industry are recommended to focus upon establishing 
working practices that will assist them to fulfil the medical device regulations. Stage 
8, involves revisiting the assessed company approximately 3 to 6 months after the 
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completion of stage 7 and reviewing progress against the SPI path. The outcome of 
this stage is an updated SPI path and a final report detailing the progress that has been 
accomplished along with additional recommendations. This stage provides feedback 
and assistance to the assessed company after a period of time and also assists in com-
piling research material in terms of SPI experiences.  
As Med-Adept is based upon the Adept method, existing Adept questions were 
used as the foundation for the Med-Adept method. Questions were added to enable 
coverage of medical device regulations. Even though each assessment component 
adopts a CMMI® process area name, it also contains questions providing coverage of 
relevant ISO/IEC 15504-5 processes and medical device standards and regulations.  
Of the 12 Adept processes, 11 had medical device regulatory questions added for 
Med-Adept the exception being Measurement and Analysis which cannot be mapped 
against the processes of IEC 62304. Additionally, the existing Adept processes (which 
Med-Adept is founded upon) did not provide coverage of 5 IEC 62304 processes 
(Software Release, Software Maintenance, Software Problem Solution, Documenta-
tion, Software Safety Classification). Therefore, the current version of Med-Adept 
also does not provide coverage of these processes. Additionally, it should also be 
noted that the current release of Med-Adept does not include a Risk Management 
process.  
Therefore Med-Adept does not provide complete coverage of all the medical de-
vice regulations. However, the main aim of Med-Adept is not to provide comprehen-
sive coverage of medical device regulations, but rather to assist organisations to im-
prove their software practices and to encourage organizations to develop medical 
device software. To encourage the uptake of the Med-Adept assessment by software 
SMEs, on-site interviewing is restricted to one day thus minimizing the time and cost 
associated with the assessment.  
4.4   Medi SPICE-Adept 
The RSRG are currently developing a new assessment method (Medi SPICE-Adept) 
that will enable lightweight assessments to be performed against the Medi SPICE 
PAM. Medi SPICE-Adept follows the same structure as Med-Adept but with several 
key differences: 
• Different processes then Med-Adept - Due to changes in the configuration of the 
processes that makeup Medi SPICE, Med Adept does not provide coverage of all 
Medi SPICE processes. Medi SPICE-Adept will provide coverage of all Medi 
SPICE processes but currently it consists of only 10 processes: Configuration 
Management, Change Request Management, Software Requirements Elicitation, 
Systems Requirements Analysis, Software Requirements Analysis, Software Con-
struction, Software Integration, Software Testing, Verification, Validation 
 
• Not based on CMMI® – Whereas, Med-Adept was founded upon CMMI® ques-
tions, ISO/IEC 15504-5  and regulatory processes Medi SPICE-Adept is not based 
upon CMMI® and does not include CMMI® questions. Medi SPICE-Adept is in-
stead based upon Medi SPICE processes. 
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• Includes agile and lean questions - Medi SPICE-Adept, unlike Med-Adept con-
tains questions that refer to agile and lean practices. The output from an assessment 
is a set of strengths, issues and recommendations.  As companies wish to increase 
the efficiency of their software development practices it was therefore considered 
essential to include agile and lean practices as part of the assessment. 
 
• Reflects changes in latest directives’ and standards - Contains processes that are 
in-line with the latest changes in the MDD and the FDA rules.  Med-Adept was ini-
tially developed to provide assessment of Medi SPICE processes that were aligned 
with ISO 12207:1995, however, both IEC 62304 and ISO/IEC 15504-5 are now 
being revised to align with ISO 12207:2008. It is therefore important that Medi 
SPICE is also revised to align with ISO 12207:2008. Therefore, Medi SPICE-
Adept provides coverage of the revised Medi SPICE processes. 
 
• May be performed over a number of days - Whereas a Med-Adept assessment 
typically involved only one day of on-site interviews, a Medi SPICE-Adept as-
sessment currently consists of 2 days of on-site interviews and provides coverage 
of 10 process areas. However, in the future we plan to extend the scope of the as-
sessment to include all 38 Medi SPICE processes and 10 subprocesses. Although, 
it will still be possible for the organization to be assessed in as few processes as 
they wish and in such cases the on-site interviews may be completed in one day. 
5   What Initial Steps May Be Taken by SMEs  
The first step for a company is to discover if their software comes under the umbrella 
of a medical device as defined by either the revision of the European Council’s MDD 
or the FDA’s MDDS. The second step will then be to become aware of what stan-
dards need to be adhered to. This can be quite a time-consuming task for organiza-
tions as there are many different standards and it is difficult to determine the complete 
list of appropriate standards and the relationship between the different standards.  
The third step is for an organization to benchmark the state of their current soft-
ware development processes against recommended best practices for medical device 
software development. In relation to this the author’s recommend adopting a Med-
Trace assessment to gain an understanding of how the traceability aspects of their 
software development processes could be improved to assist them to achieve regula-
tory compliance. Additionally, the author’s also recommend implementing a Medi 
SPICE-Adept assessment to gain an understanding as to the set of strengths and issues 
of an organization’s current software development processes in relation to developing 
regulatory compliant medical device software. The output from implementing both 
Med-Trace and Medi SPICE-Adept will be a set of recommendations that will pro-
vide a roadmap to put an organization on the correct path towards developing medical 
device software using compliant processes. It should be noted that if an organization 
decides to implement a Medi SPICE-Adept assessment this would remove the need to 
perform step 2 as this assessment is based upon Medi SPICE which provides seamless 
alignment across all the required medical device software standards. It will then be 
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important for the organization to prioritize the recommendations and start to imple-
ment them within their organization – this should be performed by implementing a 
few recommendations at a time as opposed to everything at once.  
After implementing the recommendations over a period of time the organization 
should then embark upon another Medi SPICE-Adept and/or Med-Trace assessment 
to determine the level of improvement in relation to their software development proc-
esses. The output from this follow-up assessment will either be another set of recom-
mendations or an indication that adequate processes are now in place for the organiza-
tion to contact the national notified body for an official certification. 
6   Conclusion  
The growing requirement for medical device software and the opportunities this pro-
vides for software SMEs continues to increase.  The necessity for regulatory compli-
ance and the lack of clear guidance are often cited as barriers to entry to this expand-
ing market. Organizations that are currently developing medical device software are 
mainly focused on achieving regulatory compliance rather than also improving their 
development process and increasing their efficiency. For both of these situations the 
research undertaken by the RSRG is of particular value. Medi SPICE is a process 
assessment and improvement model which is domain specific to medical device soft-
ware development.  It has been developed to address the specific requirements of 
medical device software companies.  Med-Trace and Medi SPICE-Adept (based on 
Medi SPICE and Med-Adept) are lightweight assessment methods which provide 
effective mechanisms to assist software SMEs to enable them to put processes in 
place that will enable them to perform medical device software development. The 
RSRG plan to continue to build on its extensive experience and knowledge in this 
area. It is envisaged this will include the development of additional assessment meth-
ods and tools in the future as opportunities for innovation and improvement arise. 
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